Nautre：Nanopro1000带来肿瘤精准分型诊断及治疗新策略

2015年精准医学概念提出以来，全球从事生物医学研究的科学家，寻找更新更精准的技术，以期对肿瘤进行精准分型，从而寻找最精准的药物，以达到对肿瘤精准的治疗，突破肿瘤治疗的瓶颈。

2016年10月份全球最顶级杂志Nature发表文章，以美国ProteinSimple公司Nanopro1000作为技术平台，开发肿瘤分型诊断的新策略，并指导肿瘤的精准治疗。

作者来自于世界最大的私人肿瘤研究中心：美国斯隆—凯特林癌症研究所，及康奈尔大学医学院等世界著名医学研究机构。

研究者发现，大蛋白复合体的形成，和肿瘤存活及肿瘤对于治疗药物敏感高度相关。样本来自于急性髓系白血病病人，作者将HSP90作为研究靶蛋白，使用Nanopro1000作为研究平台，研究病人机体是否会形成HSP90蛋白复合体。正常HSP90等电点在4.9，如果形成的HSP90蛋白复合体等电点大于4.9，命名为“一型”肿瘤，HSP90蛋白复合体等电点小于4.9，则命名为“二型”肿瘤。研究发现“一型”肿瘤对于HSP90抑制剂治疗敏感，“二型”肿瘤对于HSP90抑制剂不敏感，故需要选择其他治疗方法。

原文阅读：

HSP90 focused primarily as a single species at the predicted isoelectric point (pI) of 4.9. However, cancer cell lines analysed by this method contained a complex mixture of HSP90 species spanning a pI range of 4.5 to 6; HSP90α and HSP90β isoforms were part of these complexes. Furthermore, although all cancer cell lines contained a number of HSP90 complexes with pI < 4.9, a subset was enriched in HSP90 complexes with the unusual pI of ≥5, herein referred to as ‘type 1’ cells. We refer to cancer cell lines that contained mainly complexes with pI < 4.9 as ‘type 2’ cells.

Nanopro1000超灵敏蛋白质免疫检测系统，可以直接使用来自病人的微量临床穿刺样本，进行蛋白质天然结构等电聚焦分离及免疫定量，绘制病人蛋白质结构变化，翻译后修饰改变，氨基酸突变等带来的图谱变化。根据蛋白质图谱变化，绘制疾病相关诊断图谱，精准制导治疗。已经在Nature, Nature Medicine, Cell Stem cell等众多顶尖杂志发表了诊断白血病，淋巴瘤，脂肪肝等的分子分型标准，对于重新认识疾病，精准诊断，精准治疗带来了新的策略。原文阅读： To identify and separate chaperome complexes in tumours, and to overcome the limitations of classical protein chromatography methods for resolving complexes of similar composition and size, we took advantage of a capillary-based platform that combines isoelectric focusing (IEF) with immunoblotting capabilities. This methodology uses an immobilized pH gradient to separate native multimeric protein complexes based on their isoelectric point (pI), and allows for subsequent probing of immobilized complexes with specific antibodies. The method uses only minute amounts of sample, thus enabling the interrogation of primary specimens. 需要了解更多信息，请查询:www.proteinsimple.com